Pasithea Therapeutics Announces An Independent Safety Review Committee Completes Safety Review Of Data From First Dose Cohort In Phase 1 Trial Of PAS-004
Pasithea Therapeutics Announces An Independent Safety Review Committee Completes Safety Review Of Data From First Dose Cohort In Phase 1 Trial Of PAS-004
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.